{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T02:42:53Z","timestamp":1778899373933,"version":"3.51.4"},"reference-count":114,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T00:00:00Z","timestamp":1680134400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100016302","name":"Coalition for Epidemic Preparedness Innovations","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100016302","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>A defined immune profile that predicts protection against a pathogen-of-interest, is referred to as a correlate of protection (CoP). A validated SARS-CoV-2 CoP has yet to be defined, however considerable insights have been provided by pre-clinical vaccine and animal rechallenge studies which have fewer associated limitations than equivalent studies in human vaccinees or convalescents, respectively. This literature review focuses on the advantages of the use of animal models for the definition of CoPs, with particular attention on their application in the search for SARS-CoV-2 CoPs. We address the conditions and interventions required for the identification and validation of a CoP, which are often only made possible with the use of appropriate <jats:italic>in vivo<\/jats:italic> models.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1166664","type":"journal-article","created":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T05:52:54Z","timestamp":1680155574000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":7,"title":["Pre-clinical models to define correlates of protection for SARS-CoV-2"],"prefix":"10.3389","volume":"14","author":[{"given":"Caolann","family":"Brady","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom","family":"Tipton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Longet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miles W.","family":"Carroll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,3,30]]},"reference":[{"key":"B1","unstructured":"WHO director-general's opening remarks at the media briefing on COVID-19 - 11 march 20202020"},{"key":"B2","unstructured":"COVID-19 dashboard2020"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00131-10","article-title":"Correlates of protection induced by vaccination","volume":"17","author":"Plotkin","year":"2010","journal-title":"Clin Vaccine Immunol"},{"key":"B4","unstructured":"Guideline on influenza vaccines non-clinical and clinical module (EMA\/CHMP\/VWP\/457259\/2014)2016"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2021.626553","article-title":"Animal models for COVID-19: Hamsters, mouse, ferret, mink, tree shrew, and non-human primates","volume":"12","author":"Shou","year":"2021","journal-title":"Front Microbiol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9080886","article-title":"COVID-19 research: Lessons from non-human primate models","volume":"9","author":"Albrecht","year":"2021","journal-title":"Vaccines"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1010161","article-title":"Advances and gaps in SARS-CoV-2 infection models","volume":"18","author":"Mu\u00f1oz-Fontela","year":"2022","journal-title":"PloS Pathog"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1260","DOI":"10.1038\/s41467-021-21389-9","article-title":"Comparison of rhesus and cynomolgus macaques as an infection model for COVID-19","volume":"12","author":"Salguero","year":"2021","journal-title":"Nat Commun"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2599-8","article-title":"A vaccine targeting the RBD of the s protein of SARS-CoV-2 induces protective immunity","volume":"586","author":"Yang","year":"2020","journal-title":"Nature"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-03041-6","article-title":"Correlates of protection against SARS-CoV-2 in rhesus macaques","volume":"590","author":"McMahan","year":"2021","journal-title":"Nature"},{"key":"B11","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1038\/s41467-020-20642-x","article-title":"SARS-CoV-2 induces robust germinal center CD4 T follicular helper cell responses in rhesus macaques","volume":"12","author":"Shaan Lakshmanappa","year":"2021","journal-title":"Nat Commun"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1126\/science.abe2402","article-title":"REGN-COV2 antibodies prevent and treat SARS-CoV-2 infection in rhesus macaques and hamsters","volume":"370","author":"Baum","year":"2020","journal-title":"Science"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1804","DOI":"10.1016\/j.cell.2021.02.026","article-title":"Human neutralizing antibodies against SARS-CoV-2 require intact fc effector functions for optimal therapeutic protection","volume":"184","author":"Winkler","year":"2021","journal-title":"Cell"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2024671","article-title":"Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"383","author":"Corbett","year":"2020","journal-title":"New Engl J Med"},{"key":"B15","doi-asserted-by":"publisher","first-page":"3467","DOI":"10.1016\/j.cell.2021.05.040","article-title":"Low-dose Ad26.COV2.S protection against SARS-CoV-2 challenge in rhesus macaques","volume":"184","author":"He","year":"2021","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1126\/science.abc1932","article-title":"Development of an inactivated vaccine candidate for SARS-CoV-2","volume":"369","author":"Gao","year":"2020","journal-title":"Science"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2607-z","article-title":"Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques","volume":"586","author":"Mercado","year":"2020","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03275-y","article-title":"BNT162b vaccines protect rhesus macaques from SARS-CoV-2","volume":"592","author":"Vogel","year":"2021","journal-title":"Nature"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc6284","article-title":"DNA Vaccine protection against SARS-CoV-2 in rhesus macaques","volume":"369","author":"Yu","year":"2020","journal-title":"Science"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1101\/2020.12.23.424138","article-title":"mRNA vaccine CVnCoV protects non-human primates from SARS-CoV-2 challenge infection","author":"Rauch","year":"2020","journal-title":"bioRxiv"},{"key":"B21","doi-asserted-by":"publisher","first-page":"eabg7996","DOI":"10.1126\/sciadv.abg7996","article-title":"Immunological and pathological outcomes of SARS-CoV-2 challenge following formalin-inactivated vaccine in ferrets and rhesus macaques","volume":"7","author":"Bewley","year":"2021","journal-title":"Sci Adv"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20202756","article-title":"Immunogenicity and efficacy of one and two doses of Ad26.COV2.S COVID vaccine in adult and aged NHP","volume":"218","author":"Solforosi","year":"2021","journal-title":"J Exp Med"},{"key":"B23","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/s42003-021-02443-0","article-title":"ChAdOx1 nCoV-19 protection against SARS-CoV-2 in rhesus macaque and ferret challenge models","volume":"4","author":"Lambe","year":"2021","journal-title":"Commun Biol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2608-y","article-title":"ChAdOx1 nCoV-19 vaccine prevents SARS-CoV-2 pneumonia in rhesus macaques","volume":"586","author":"van Doremalen","year":"2020","journal-title":"Nature"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-03530-2","article-title":"Adjuvanting a subunit COVID-19 vaccine to induce protective immunity","volume":"594","author":"Arunachalam","year":"2021","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"4207","DOI":"10.1038\/s41467-020-18077-5","article-title":"An adenovirus-vectored COVID-19 vaccine confers protection from SARS-COV-2 challenge in rhesus macaques","volume":"11","author":"Feng","year":"2020","journal-title":"Nat Commun"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.xcrm.2021.100405","article-title":"Fab and fc contribute to maximal protection against SARS-CoV-2 following NVX-CoV2373 subunit vaccine with matrix-m vaccination","volume":"2","author":"Gorman","year":"2021","journal-title":"Cell Rep Med"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.01503-21","article-title":"Recovery from acute SARS-CoV-2 infection and development of anamnestic immune responses in T cell-depleted rhesus macaques","volume":"12","author":"Hasenkrug","year":"2021","journal-title":"mBio"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04587-3","article-title":"Cell transcriptomic atlas of the non-human primate macaca fasicularis","volume":"604","author":"Han","year":"2020","journal-title":"Nature"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04231-6","article-title":"Optimization of non-coding regions for a non-modified mRNA COVID-19 vaccine","volume":"601","author":"Gebre","year":"2022","journal-title":"Nature"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2020.10.064","article-title":"NVX-CoV2373 vaccine protects cynomolgus macaque upper and lower airways against SARS-CoV-2 challenge","volume":"38","author":"Guebre-Xabier","year":"2020","journal-title":"Vaccine"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-1070-6","article-title":"Ad26 vaccine protects against SARS-CoV-2 severe clinical disease in hamsters","volume":"26","author":"Tostanoski","year":"2020","journal-title":"Nat Med"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.3390\/v12070779","article-title":"Age-dependent progression of SARS-CoV-2 infection in Syrian hamsters","volume":"12","author":"Osterrieder","year":"2020","journal-title":"Viruses"},{"key":"B34","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2020.579330","article-title":"Tissue distribution of ACE2 protein in Syrian golden hamster (Mesocricetus auratus) and its possible implications in SARS-CoV-2 related studies","volume":"11","author":"Suresh","year":"2021","journal-title":"Front Pharmacol"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1126\/science.abc7520","article-title":"Isolation of potent SARS-CoV-2 neutralizing antibodies and protection from disease in a small animal model","volume":"369","author":"Rogers","year":"2020","journal-title":"Science"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj3321","article-title":"Broad betacoronavirus neutralization by a stem helix-specific human antibody","volume":"373","author":"Pinto","year":"2021","journal-title":"Science"},{"key":"B37","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41541-021-00311-w","article-title":"mRNA-based SARS-CoV-2 vaccine candidate CVnCoV induces high levels of virus-neutralising antibodies and mediates protection in rodents","volume":"6","author":"Rauch","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109400","article-title":"A single intranasal or intramuscular immunization with chimpanzee adenovirus-vectored SARS-CoV-2 vaccine protects against pneumonia in hamsters","volume":"36","author":"Bricker","year":"2021","journal-title":"Cell Rep"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abh0755","article-title":"Intranasal ChAdOx1 nCoV-19\/AZD1222 vaccination reduces viral shedding after SARS-CoV-2 D614G challenge in preclinical models","volume":"13","author":"Doremalen","year":"2021","journal-title":"Sci Transl Med"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2100421","article-title":"Cutting edge: Nucleocapsid vaccine elicits spike-independent SARS-CoV-2 protective immunity","volume":"207","author":"Matchett","year":"2021","journal-title":"J Immunol"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2787-6","article-title":"Animal models for COVID-19","volume":"586","author":"Mu\u00f1oz-Fontela","year":"2020","journal-title":"Nature"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2708-8","article-title":"A mouse-adapted model of SARS-CoV-2 to test COVID-19 countermeasures","volume":"586","author":"Dinnon","year":"2020","journal-title":"Nature"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.2000583","article-title":"A potently neutralizing antibody protects mice against SARS-CoV-2 infection","volume":"205","author":"Alsoussi","year":"2020","journal-title":"J Immunol"},{"key":"B44","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2548-6","article-title":"Potently neutralizing and protective human antibodies against SARS-CoV-2","volume":"584","author":"Zost","year":"2020","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1038\/s41467-020-20653-8","article-title":"SARS-CoV-2 spike glycoprotein vaccine candidate NVX-CoV2373 immunogenicity in baboons and protection in mice","volume":"12","author":"Tian","year":"2021","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1016\/j.medj.2020.12.006","article-title":"A booster dose enhances immunogenicity of the COVID-19 vaccine candidate ChAdOx1 nCoV-19 in aged mice","volume":"2","author":"Silva-Cayetano","year":"2021","journal-title":"Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2622-0","article-title":"SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness","volume":"586","author":"Corbett","year":"2020","journal-title":"Nature"},{"key":"B48","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/s41467-020-20439-y","article-title":"Dose-dependent response to infection with SARS-CoV-2 in the ferret model and evidence of protective immunity","volume":"12","author":"Ryan","year":"2021","journal-title":"Nat Commun"},{"key":"B49","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1038\/s41541-021-00315-6","article-title":"ChAdOx1 nCoV-19 (AZD1222) vaccine candidate significantly reduces SARS-CoV-2 shedding in ferrets","volume":"6","author":"Marsh","year":"2021","journal-title":"NPJ Vaccines"},{"key":"B50","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41392-020-00269-6","article-title":"Comparison of nonhuman primates identified the suitable model for COVID-19","volume":"5","author":"Lu","year":"2020","journal-title":"Signal Transduction Targeted Ther"},{"key":"B51","doi-asserted-by":"publisher","first-page":"16007","DOI":"10.1038\/s41598-020-72563-w","article-title":"Susceptibility of tree shrew to SARS-CoV-2 infection","volume":"10","author":"Zhao","year":"2020","journal-title":"Sci Rep"},{"key":"B52","doi-asserted-by":"publisher","first-page":"517","DOI":"10.24272\/j.issn.2095-8137.2020.053","article-title":"COVID-19-like symptoms observed in Chinese tree shrews infected with SARS-CoV-2","volume":"41","author":"Xu","year":"2020","journal-title":"Zoological Res"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(20)30089-6","article-title":"SARS-CoV-2 in fruit bats, ferrets, pigs, and chickens: an experimental transmission study","volume":"1","author":"Schlottau","year":"2020","journal-title":"Lancet Microbe"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1126\/science.abb7015","article-title":"Susceptibility of ferrets, cats, dogs, and other domesticated animals to SARS\u2013coronavirus 2","volume":"368","author":"Shi","year":"2020","journal-title":"Science"},{"key":"B55","unstructured":"R&D blueprint COVID-19 animal models2020"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1126\/science.1139247","article-title":"Evolutionary and biomedical insights from the rhesus macaque genome","volume":"316","author":"Gibbs","year":"2007","journal-title":"Science"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.micinf.2020.03.003","article-title":"Predicting the angiotensin converting enzyme 2 (ACE2) utilizing capability as the receptor of SARS-CoV-2","volume":"22","author":"Qiu","year":"2020","journal-title":"Microbes infection"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.2807\/1560-7917.ES.2020.25.23.2001005","article-title":"SARS-CoV-2 infection in farmed minks, the Netherlands, April and may 2020","volume":"25","author":"Oreshkova","year":"2020","journal-title":"Euro Surveill"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-021-04186-8","article-title":"Pre-existing polymerase-specific T cells expand in abortive seronegative SARS-CoV-2","volume":"601","author":"Swadling","year":"2022","journal-title":"Nature"},{"key":"B60","doi-asserted-by":"publisher","first-page":"1251","DOI":"10.1038\/s41467-022-28898-1","article-title":"Divergent trajectories of antiviral memory after SARS-CoV-2 infection","volume":"13","author":"Tomic","year":"2022","journal-title":"Nat Commun"},{"key":"B61","doi-asserted-by":"publisher","first-page":"2055","DOI":"10.1038\/s41467-021-21856-3","article-title":"T Cell assays differentiate clinical and subclinical SARS-CoV-2 infections from cross-reactive antiviral responses","volume":"12","author":"Ogbe","year":"2021","journal-title":"Nat Commun"},{"key":"B62","doi-asserted-by":"publisher","DOI":"10.1101\/2020.11.02.20222778","article-title":"SARS-CoV-2 responsive T cell numbers and anti-spike IgG levels are both associated with protection from COVID-19: A prospective cohort study in keyworkers","author":"Wyllie","year":"2021","journal-title":"medRxiv"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1016\/s0140-6736(21)00675-9","article-title":"SARS-CoV-2 infection rates of antibody-positive compared with antibody-negative health-care workers in England: a large, multicentre, prospective cohort study (SIREN)","volume":"397","author":"Hall","year":"2021","journal-title":"Lancet"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034545","article-title":"Antibody status and incidence of SARS-CoV-2 infection in health care workers","volume":"384","author":"Lumley","year":"2020","journal-title":"New Engl J Med"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1016\/S2666-5247(21)00146-4","article-title":"Blood transcriptional biomarkers of acute viral infection for detection of pre-symptomatic SARS-CoV-2 infection: a nested, case-control diagnostic accuracy study","volume":"2","author":"Gupta","year":"2021","journal-title":"Lancet Microbe"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.1060438","article-title":"IFI27 transcription is an early predictor for COVID-19 outcomes, a multi-cohort observational study","volume":"13","author":"Shojaei","year":"2023","journal-title":"Front Immunol"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2020","journal-title":"New Engl J Med"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107058","article-title":"Prevention and attenuation of covid-19 with the BNT162b2 and mRNA-1273 vaccines","volume":"385","author":"Thompson","year":"2021","journal-title":"New Engl J Med"},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01540-1","article-title":"Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection","volume":"27","author":"Feng","year":"2021","journal-title":"Nat Med"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2107659","article-title":"Safety and efficacy of NVX-CoV2373 covid-19 vaccine","volume":"385","author":"Heath","year":"2021","journal-title":"New Engl J Med"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01780-9","article-title":"Safety, tolerability and viral kinetics during SARS-CoV-2 human challenge in young adults","volume":"28","author":"Killingley","year":"2022","journal-title":"Nat Med"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab574","article-title":"Immunogenicity of SCB-2019 coronavirus disease 2019 vaccine compared with 4 approved vaccines","volume":"225","author":"Ambrosino","year":"2022","journal-title":"J Infect Dis"},{"key":"B73","doi-asserted-by":"publisher","first-page":"e145476","DOI":"10.1172\/JCI145476","article-title":"SARS-CoV-2-specific CD8+ T cell responses in convalescent COVID-19 individuals","volume":"131","author":"Kared","year":"2021","journal-title":"J Clin Invest"},{"key":"B74","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41590-021-01084-z","article-title":"An immunodominant NP105\u2013113-B*07:02 cytotoxic T cell response controls viral replication and is associated with less severe COVID-19 disease","volume":"23","author":"Peng","year":"2022","journal-title":"Nat Immunol"},{"key":"B75","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abg5669","article-title":"CD8+ T cells specific for conserved coronavirus epitopes correlate with milder disease in patients with COVID-19","volume":"6","author":"Mallajosyula","year":"2021","journal-title":"Sci Immunol"},{"key":"B76","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abk3070","article-title":"Allelic variation in class I HLA determines CD8+ T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2","volume":"7","author":"Francis","year":"2022","journal-title":"Sci Immunol"},{"key":"B77","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1038\/s41467-021-27674-x","article-title":"Cross-reactive memory T cells associate with protection against SARS-CoV-2 infection in COVID-19 contacts","volume":"13","author":"Kundu","year":"2022","journal-title":"Nat Commun"},{"key":"B78","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.cell.2020.04.026","article-title":"Imbalanced host response to SARS-CoV-2 drives development of COVID-19","volume":"181","author":"Blanco-Melo","year":"2020","journal-title":"Cell"},{"key":"B79","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.cell.2020.05.015","article-title":"Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals","volume":"181","author":"Grifoni","year":"2020","journal-title":"Cell"},{"key":"B80","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.cell.2020.09.038","article-title":"Antigen-specific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity","volume":"183","author":"Rydyznski Moderbacher","year":"2020","journal-title":"Cell"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1126\/science.abj0299","article-title":"Immune correlates of protection by mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates","volume":"373","author":"Corbett","year":"2021","journal-title":"Science"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(21)00677-0","article-title":"Efficacy and safety of the CVnCoV SARS-CoV-2 mRNA vaccine candidate in ten countries in Europe and Latin America (HERALD): a randomised, observer-blinded, placebo-controlled, phase 2b\/3 trial","volume":"22","author":"Kremsner","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B83","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines10081251","article-title":"Optimised non-coding regions of mRNA SARS-CoV-2 vaccine CV2CoV improves homologous and heterologous neutralising antibody responses","volume":"10","author":"Roth","year":"2022","journal-title":"Vaccines"},{"key":"B84","doi-asserted-by":"publisher","first-page":"4048","DOI":"10.1038\/s41467-021-24339-7","article-title":"CVnCoV and CV2CoV protect human ACE2 transgenic mice from ancestral b BavPat1 and emerging B.1.351 SARS-CoV-2","volume":"12","author":"Hoffmann","year":"2021","journal-title":"Nat Commun"},{"key":"B85","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2034201","article-title":"Interim results of a phase 1\u20132a trial of Ad26.COV2.S covid-19 vaccine","volume":"384","author":"Sadoff","year":"2021","journal-title":"New Engl J Med"},{"key":"B86","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, south Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110345","article-title":"Safety and efficacy of the BNT162b2 mRNA covid-19 vaccine through 6 months","volume":"385","author":"Thomas","year":"2021","journal-title":"New Engl J Med"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2027906","article-title":"Safety and immunogenicity of two RNA-based covid-19 vaccine candidates","volume":"383","author":"Walsh","year":"2020","journal-title":"New Engl J Med"},{"key":"B89","doi-asserted-by":"publisher","first-page":"eabi6950","DOI":"10.1126\/sciimmunol.abi6950","article-title":"Distinct antibody and memory b cell responses in SARS-CoV-2 na\u00efve and recovered individuals following mRNA vaccination","volume":"6","author":"Goel","year":"2021","journal-title":"Sci Immunol"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.vaccine.2021.05.063","article-title":"Evidence for antibody as a protective correlate for COVID-19 vaccines","volume":"39","author":"Earle","year":"2021","journal-title":"Vaccine"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.857481","article-title":"Complement-mediated neutralisation identified in Ebola virus disease survivor plasma: Implications for protection and pathogenesis","volume":"13","author":"Mellors","year":"2022","journal-title":"Front Immunol"},{"key":"B92","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01179-4","article-title":"Phase 1\/2 trial of SARS-CoV-2 vaccine ChAdOx1 nCoV-19 with a booster dose induces multifunctional antibody responses","volume":"27","author":"Barrett","year":"2021","journal-title":"Nat Med"},{"key":"B93","doi-asserted-by":"publisher","DOI":"10.1038\/s41385-018-0080-x","article-title":"Sustained protective immunity against bordetella pertussis nasal colonization by intranasal immunization with a vaccine-adjuvant combination that induces IL-17-secreting TRM cells","volume":"11","author":"Allen","year":"2018","journal-title":"Mucosal Immunol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"554","DOI":"10.3390\/vaccines8030554","article-title":"Inflammasome-mediated immunogenicity of clinical and experimental vaccine adjuvants","volume":"8","author":"Reinke","year":"2020","journal-title":"Vaccines"},{"key":"B95","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.1016\/j.immuni.2020.11.009","article-title":"SARS-CoV-2 mRNA vaccines foster potent antigen-specific germinal center responses associated with neutralizing antibody generation","volume":"53","author":"Lederer","year":"2020","journal-title":"Immunity"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abj7211","article-title":"AZD1222\/ChAdOx1 nCoV-19 vaccination induces a polyfunctional spike protein-specific Th1 response with a diverse TCR repertoire","volume":"13","author":"Swanson","year":"2021","journal-title":"Sci Trans Med"},{"key":"B97","doi-asserted-by":"publisher","first-page":"afac115","DOI":"10.1093\/ageing\/afac115","article-title":"Effectiveness of BNT162b2 and ChAdOx-1 vaccines in residents of long-term care facilities in England using a time-varying proportional hazards model","volume":"51","author":"Paranthaman","year":"2022","journal-title":"Age Ageing"},{"key":"B98","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1016\/j.cell.2022.01.027","article-title":"Germinal center responses to SARS-CoV-2 mRNA vaccines in healthy and immunocompromised individuals","volume":"185","author":"Lederer","year":"2022","journal-title":"Cell"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00583-2","article-title":"Mucosal vaccines \u2014 fortifying the frontiers","volume":"22","author":"Lavelle","year":"2022","journal-title":"Nat Rev Immunol"},{"key":"B100","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1056\/NEJMoa030595","article-title":"Use of the inactivated intranasal influenza vaccine and the risk of bell's palsy in Switzerland","volume":"350","author":"Mutsch","year":"2004","journal-title":"New Engl J Med"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1126\/sciimmunol.abo0226","article-title":"A modified vaccinia Ankara vaccine expressing spike and nucleocapsid protects rhesus macaques against SARS-CoV-2 delta infection","volume":"7","author":"Routhu","year":"2022","journal-title":"Sci Immunol"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1126\/science.abo2523","article-title":"Unadjuvanted intranasal spike vaccine elicits protective mucosal immunity against sarbecoviruses","volume":"378","author":"Mao","year":"2022","journal-title":"Science"},{"key":"B103","doi-asserted-by":"publisher","first-page":"724","DOI":"10.1016\/j.immuni.2020.07.019","article-title":"A single immunization with nucleoside-modified mRNA vaccines elicits strong cellular and humoral immune responses against SARS-CoV-2 in mice","volume":"53","author":"Laczk\u00f3","year":"2020","journal-title":"Immunity"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00569-12","article-title":"Frequent and strong antibody-mediated natural killer cell activation in response to HIV-1 env in individuals with chronic HIV-1 infection","volume":"86","author":"Thobakgale Christina","year":"2012","journal-title":"J Virol"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.867015","article-title":"A comprehensive atlas of immunological differences between humans, mice, and non-human primates","volume":"13","author":"Bjornson-Hooper","year":"2022","journal-title":"Front Immunol"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2013.00032","article-title":"No monkey business: why studying NK cells in non-human primates pays off","volume":"4","author":"Hong","year":"2013","journal-title":"Front Immunol"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.4049\/jimmunol.174.4.2185","article-title":"Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251","volume":"174","author":"G\u00f3mez-Rom\u00e1n","year":"2005","journal-title":"J Immunol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/nprot.2016.157","article-title":"Immuno-engineered organoids for regulating the kinetics of b-cell development and antibody production","volume":"12","author":"Purwada","year":"2017","journal-title":"Nat Protoc"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.1021\/acsbiomaterials.6b00474","article-title":"Modular immune organoids with integrin ligand specificity differentially regulate ex vivo b cell activation","volume":"3","author":"Purwada","year":"2017","journal-title":"ACS Biomaterials Sci Eng"},{"key":"B110","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41467-017-01029-x","article-title":"EZH2 enables germinal centre formation through epigenetic silencing of CDKN1A and an Rb-E2F1 feedback loop","volume":"8","author":"B\u00e9guelin","year":"2017","journal-title":"Nat Commun"},{"key":"B111","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1126\/science.abm3425","article-title":"Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial","volume":"375","author":"Gilbert","year":"2022","journal-title":"Science"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/S1473-3099(22)00502-3","article-title":"Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-s in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial","volume":"22","author":"Lazarus","year":"2022","journal-title":"Lancet Infect Dis"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2208343","article-title":"A bivalent omicron-containing booster vaccine against covid-19","volume":"387","author":"Chalkias","year":"2022","journal-title":"New Engl J Med"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc2213907","article-title":"Antibody response to omicron BA.4\u2013BA.5 bivalent booster","volume":"388","author":"Wang","year":"2023","journal-title":"New Engl J Med"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1166664\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,30]],"date-time":"2023-03-30T05:52:59Z","timestamp":1680155579000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1166664\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,30]]},"references-count":114,"alternative-id":["10.3389\/fimmu.2023.1166664"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1166664","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,30]]},"article-number":"1166664"}}